RBC Capital Markets Lowers Price Target on IDEAYA Biosciences to $45

RBC Capital Markets has revised its price target for IDEAYA Biosciences, Inc. (NASDAQ: IDYA), lowering it to $45 from the previous target of $48. Despite the adjustment, the firm maintained its 'Outperform' rating on the stock, which it continues to categorize under speculative risk. This analyst action follows the company's recent third-quarter 2026 financial results.